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Abstract
BACKGROUND 
Cystic pancreatic lesions consist of a wide variety of lesions that are becoming 
increasingly diagnosed with the growing use of imaging techniques. Of these, 
mucinous cysts are especially relevant due to their risk of malignancy. However, 
morphological findings are often suboptimal for their differentiation. Endoscopic 
ultrasound fine-needle aspiration (EUS-FNA) with molecular analysis has been 
suggested to improve the diagnosis of pancreatic cysts.
AIM 
To determine the impact of molecular analysis on the detection of mucinous cysts 
and malignancy.
METHODS 
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An 18-month prospective observational study of consecutive patients with 
pancreatic cystic lesions and an indication for EUS-FNA following European 
clinical practice guidelines was conducted. These cysts included those > 15 mm 
with unclear diagnosis, and a change in follow-up or with concerning features in 
which results might change clinical management. EUS-FNA with cytological, 
biochemical and glucose and molecular analyses with next-generation sequencing 
were performed in 36 pancreatic cysts. The cysts were classified as mucinous and 
non-mucinous by the combination of morphological, cytological and biochemical 
analyses when surgery was not performed. Malignancy was defined as cytology 
positive for malignancy, high-grade dysplasia or invasive carcinoma on surgical 
specimen, clinical or morphological progression, metastasis or death related to 
neoplastic complications during the 6-mo follow-up period. Next-generation 
sequencing results were compared for cyst type and malignancy.
RESULTS 
Of the 36 lesions included, 28 (82.4%) were classified as mucinous and 6 (17.6%) as 
non-mucinous. Furthermore, 5 (13.9%) lesions were classified as malignant. The 
amount of deoxyribonucleic acid obtained was sufficient for molecular analysis in 
25 (69.4%) pancreatic cysts. The amount of intracystic deoxyribonucleic acid was 
not statistically related to the cyst fluid volume obtained from the lesions. 
Analysis of KRAS and/or GNAS showed 83.33% [95% confidence interval (CI): 
63.34-100] sensitivity, 60% (95%CI: 7.06-100) specificity, 88.24% (95%CI: 69.98-100) 
positive predictive value and 50% (95%CI: 1.66-98.34) negative predictive value (P 
= 0.086) for the diagnosis of mucinous cystic lesions. Mutations in KRAS and 
GNAS were found in 2/5 (40%) of the lesions classified as non-mucinous, thus 
recategorizing those lesions as mucinous neoplasms, which would have led to a 
modification of the follow-up plan in 8% of the cysts in which molecular analysis 
was successfully performed. All 4 (100%) malignant cysts in which molecular 
analysis could be performed had mutations in KRAS and/or GNAS, although they 
were not related to malignancy (P > 0.05). None of the other mutations analyzed 
could detect mucinous or malignant cysts with statistical significance (P > 0.05).
CONCLUSION 
Molecular analysis can improve the classification of pancreatic cysts as mucinous 
or non-mucinous. Mutations were not able to detect malignant lesions.
Key Words: Pancreatic cysts; Molecular analysis; Next-generation sequencing; Mucinous 
cyst; Pancreatic cyst fluid; Pancreatic cancer
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Core Tip: Pancreatic cystic lesions are frequently found on imaging studies performed 
for other reasons, but differentiation between the different types and the detection of 
malignancy is often suboptimal with morphological features. Molecular analysis has 
been proposed to optimize cyst classification and the detection of malignancy. 
However, there is little evidence of its feasibility and usefulness in daily practice. The 
aim of this study was to evaluate the diagnostic yield of molecular analysis for the 
detection of mucinous and malignant cysts in routine clinical practice.
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Pancreatic cysts are increasingly diagnosed as a consequence of both incidental 
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findings on computed tomography (CT) and magnetic resonance imaging (MRI)[1], and 
longer life expectancy of the population[2,3]. Their diagnosis can generate a high degree 
of concern for both patients and physicians leading sometimes to the performance of 
multiple examinations, associated with an increase in diagnostic costs, and even 
unnecessary resections.
There are many different types of pancreatic cysts, including both neoplastic and 
non-neoplastic lesions. Their accurate diagnosis is important as some of them, such as 
mucinous cystic lesions or solid pseudopapillary tumors, are associated with a risk of 
malignancy, whereas others, such as serous cystic neoplasms and pseudocysts, are 
considered benign cysts. Mucinous cysts have a higher risk of malignant 
transformation. They can be divided into mucinous cystic neoplasm (MCN) and 
intraductal papillary mucinous neoplasm (IPMN), which can be branch-duct IPMN, 
mixed-type IPMN or main-duct IPMN (MD-IPMN). However, not all of them have the 
same risk of malignancy. According to recent publications, MCN have a 10%-17% risk 
of malignancy[4,5], MD-IPMN 38%-68%[2,6,7], branch-duct IPMN 12%-47%[2,6], and solid 
pseudopapillary neoplasms 8%-20%[6]. Furthermore, it is also important to note that 
the presence of an IPMN is associated with a higher risk of developing concomitant 
pancreatic adenocarcinoma[8,9].
Pancreatic neoplasia is one of the most frequent causes of cancer-related death, with 
a 5-year survival lower than 10%[9]. Only 20%-25% of pancreatic neoplasms are 
candidates for surgical treatment at diagnosis, and 80% of these will recur despite 
surgical intervention. Precursor lesions of pancreatic adenocarcinoma are pancreatic 
intraepithelial neoplasia and pancreatic cystic neoplasm (PCN)[10], and their 
identification is crucial for early diagnosis and treatment, thus increasing survival of 
these patients.
Hence, the main diagnostic challenge for these lesions is the early detection of 
preneoplastic and malignant lesions, thereby avoiding unnecessary surgeries and 
establishing an adequate follow-up due to the risk of degeneration and the 
development of pancreatic adenocarcinoma. Therefore, an accurate diagnosis has 
prognostic, therapeutic and follow-up implications. Most PCN are incidentally 
detected in radiological tests performed for other reasons. However, in many cases it is 
difficult to differentiate between the different types of cysts and their risk of 
malignancy only by morphological characteristics, with an accuracy for adequate 
identification of the type of cyst of 40%-95% for MRI and 40%-81% for CT[11].
Endoscopic ultrasound (EUS) is currently the diagnostic technique of choice for 
PCN as it allows not only assessment of morphological criteria, but also the 
performance of fine needle aspiration (FNA) and fluid analysis[12]. Usually, cyst fluid 
analysis includes cytological and biochemical [carcinoembryonic antigen (CEA), and 
recently glucose] evaluation[13-16]. However, accuracy for the diagnosis of mucinous 
cysts and malignancy detection remains suboptimal[14,17]. There are different clinical 
practice guidelines for the diagnosis and treatment of PCN. The most commonly used 
are the International Association of Pancreatology guideline (IAP), the European 
guideline and the American Gastroenterological Association (AGA) guideline[3,11,18]. 
However, the IAP and the European guidelines lead to unnecessary surgeries and the 
AGA to a decrease in sensitivity for the detection of malignancy[5]. Therefore, multiple 
authors have evaluated the possibility of incorporating molecular analysis of cyst fluid 
for the diagnosis of pancreatic cysts, which has shown promising results[14,19,20].
The aim of the current study was to determine the impact of molecular analysis on 
the detection of mucinous cysts and malignancy in routine clinical practice.
MATERIALS AND METHODS
This prospective trial was conducted in patients from a single center (Hospital 
Universitario de La Princesa, Madrid, Spain) over an 18-mo period.
Case selection
Consecutive patients over 18 years old referred to the Endoscopy Unit of Hospital 
Universitario de La Princesa with PCN and an indication for EUS-FNA following 
current clinical practice guidelines were recruited for the study. Inclusion criteria 
were: Lesions ≥ 15 mm in size, the need to confirm the diagnosis prior to surgical 
treatment, presence of worrisome features on imaging (wall thickening, main 
pancreatic duct > 5 mm, non-enhanced mural nodule, abrupt change in the size of the 
main pancreatic duct), changes on imaging during follow-up or an increase in serum 
CA 19.9. Patients were excluded from enrolment according to the following criteria: 
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Pregnancy, cysts with extra-pancreatic location or outside the scope of EUS, previous 
study with EUS-FNA, active treatment with anticoagulants or antiplatelets, 
thrombopenia (< 50.000 platelets/µL) or coagulopathy (INR < 1.5), or refusal to 
participate in the study. All participants enrolled in the study provided informed 
consent prior to the procedure. The study was approved by the Research Ethics 
Committee and prospectively registered on Clinical Trials (NCT03740360).
Imaging features prior to cyst fluid analysis
Radiological imaging impression was obtained by reviewing the radiological reports, 
and cysts were classified as malignant or without malignant features. A single 
endoscopist and anesthetist, both experts in their fields, performed the respective 
procedures in all study participants. All EUS were performed with a linear endoscopic 
ultrasound device (GF-UCT 180; Olympus Co., Japan). EUS features were described 
and recorded during the procedure, and lesions were classified as with or without 
worrisome features, and as malignant, mucinous or serous. After examination of the 
lesions contrast-enhanced EUS with Sonovue® (sulfur hexafluoride-filled 
microbubbles) was performed and the examination was recorded for later detailed re-
evaluation. We defined three contrast patterns based on the cyst wall and septal 
enhancement: Hyper-enhanced, hypo-/iso-enhanced and mixed pattern.
Cyst fluid analysis
After antibiotic prophylaxis with 400 mg iv ciprofloxacin or 2 g ceftriaxone in the case 
of allergy to quinolones, cyst fluid was obtained by EUS-FNA with a 22 G needle 
(Expert Slimline, Boston®), and sent for cytologic, biochemical and molecular analysis. 
Both immediate and delayed (after 72 h) complications were registered.
Cytological evaluation: Smears were prepared on glass slides, 2/3 air-dried and 1/3 
fixed in ethanol. Mucin staining with Alcian blue was performed on ethanol-fixed 
slides, and mucin detection was performed with the automatic Dakocitomation system 
(AR160). Lesions were categorized under Papanicolau classification and as mucin-
staining positive or negative.
Biochemical analysis: At least 1 mL of cyst fluid was sent for analysis. We determined 
CEA levels in our laboratory with the Architect system by chemiluminescent 
immunoassay. Following prior studies, the CEA cut-off point was established as 192 
ng/mL to differentiate mucinous (< 192 ng/mL) from non-mucinous. From the 16th 
lesion included in the study, intracystic glucose determination was added to the 
protocol, as recent evidence indicates that glucose levels < 50 mg/dL are suggestive of 
mucinous cysts[15,16]. Glucose determination was performed in our Hospital laboratory 
(using calibration for the determination of glucose in biological fluids).
Molecular analysis: After cytological and biochemical analysis, the excess fluid was 
frozen and stored at -80ºC until all patients were recruited. The range of volumes 
available for molecular analysis was 0.3-5 mL. The collection was registered in the 
Spanish National Register of Biobanks of the Carlos III Health Institute. The genomic 
deoxyribonucleic acid (DNA) present in the pancreatic cyst fluid was manually 
purified using the NZY Blood gDNa Isolation kit (NZYtech) following the 
manufacturer's recommendations. The extracted DNA was fluorimetrically quantified 
using the Quantus (Promega) system. The integrity of the DNA obtained was 
determined in the Agilent 2100 Bioanalyzer (Agilent) using the Agilent High 
Sensitivity DNA (Agilent) kit. Due to the low concentrations obtained in some 
samples, DNA was concentrated up to a concentration of 30 ng/uL, using magnetic 
beads (AMPure XP beads, Beckman Coulter). Although cyst fluid was initially 
obtained from the 36 pancreatic cysts, only 25 of them yielded the amount of DNA 
needed to perform sequencing (100 ng of DNA at a concentration of 30 ng/uL). The 
targeted Next-Generation Sequencing (tNGS) was performed in the MiSeqTM 
platform (Illumina) using a panel designed specifically for this project (Roche).
Gene panel bioinformatic design 
All exons of the following genes were included and sequenced by tNGS: AKT1, ALK, 
APC, BRAF, CDKN2A, CDH1, CTNNB1, DDR2, EGFR, ERBB2, ESR1, FBXW7, FGFR1, 
FGFR2, FGFR3, FOXL2, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, 
MAP2K1, MET, NOTCH1, NRAS, PDGFRA, PIK3CA, PIK3R1, PTEN, RET, RNF43, 
ROS1, SMAD4, TGFBR2, TP53, VHL. Therefore, coverage was complete.
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tNGS data analysis
Coverage analysis showed that nearly 100% of the regions were covered at a depth of 
100 × or more in all the samples, reaching 400 × in a very high percentage of them. The 
search for variants was carried out with the VarScan software (http://varscan.
sourceforge.net/). Among the variants identified, approximately 400, those present in 
more than 75% of the samples which did not appear as mutations noted in the 
databases were excluded as they were not likely to participate in the development of 
the disease. Variants with very low frequency (< 1 reading) were eliminated from the 
study since these could be due to errors in sequencing. For the final analysis, the 
variants detected with a frequency between 1%-33% were included. A total of 78 
variants were detected in the 25 samples analyzed (mean of 3 mutations per sample). 
Comparisons between samples and identification of the pathogenicity of variants were 
carried out using the PredictSNP2tool (https://Loschmidt.chemi.muni.cz/
predictsnp2/referencia). In addition, the information from the predictive tools was 
combined with the results of the search in the ClinVar database, which contains the 
interpretation of the relationship between variants and their significance for human 
health.
Diagnostic criteria for malignant/benign cysts
We defined as malignant those PCN that met any of the following criteria[21]: EUS-FNA 
cytology suspicious or compatible with malignancy; High-grade dysplasia or invasive 
carcinoma in the histology analysis of a surgical specimen; Progression of the PCN 
and/or metastatic disease in the imaging tests during follow-up; Death related to 
neoplastic complications up to 6 mo after diagnosis; Clinical follow-up consistent with 
underlying tumor disease for 6 mo.
In the absence of a definitive histopathological diagnosis, we defined a "pseudo-
gold standard" to classify lesions into mucinous and non-mucinous (Figure 1), based 
on the previous evidence and the recommendations of clinical practice 
guidelines[3,10,11,22].
Variables
The following data were recorded for each patient: Age, sex, American Society of 
Anesthesiologist classification, treatment with antiplatelets or anticoagulants, history 
of pancreatitis, neoplasia, smoking or familial pancreatic cancer, presence of 
symptoms, radiological diagnosis, date of EUS examination, EUS diagnosis, 
complications, size and location of the lesions, biochemical, cytological and molecular 
analysis of cyst fluid, histopathological diagnosis in the case of surgery, follow-up and 
diagnosis of malignancy following the above-mentioned criteria.
Statistical analysis
Continuous variables are expressed as average ± SD and were compared between 
groups using the Student’s t-test or U Mann-Whitney test. Categorical variables are 
expressed as percentage, and comparisons were made with the c2 or Fisher´s exact test. 
The level of agreement reached was determined with Cohen's kappa. Sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) of 
diagnostic variables were determined according to the pseudo-gold standard 
established in the study. P values ≤ 0.05 were considered significant. All the statistical 
analyses were performed with the IBM SPSS 23.0 or Stata v13.0 program.
RESULTS
Patient baseline characteristics
Eighty-seven patients with a total of 95 PCN were included between June 2017 and 
December 2018. After applying the exclusion criteria, 52 patients with 59 PCN were 
excluded: 47 lesions < 15 mm in size, 6 patients with 6 PCN did not agree to 
participate, 4 due to lack of modification of the plan following the results of EUS-FNA, 
and 2 lesions due to lack of technical safety to reach the lesion. In one of these cases 
access was limited by interposition of gastric neoplasia. Thus, 35 patients with 36 PCN 
were initially enrolled. Demographic and clinical characteristics are detailed in Table 1.
Lesion characteristics
Table 2 summarizes the lesion characteristics on radiological (CT and MRI) and EUS 
examinations. None of the 8 mural nodules detected on EUS were described in the 
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Table 1 Demographic and clinical data of the study population, n (%)
Patients n = 35
Age (yr) 66.7 ± 14.5
Male gender 17 (48.6)
ASA I-II 25 (71.4)
AAS 5 (14.3)
Smoking 12 (34.3)
History of acute pancreatitis 3 (8.6)
History of extrapancreatic neoplasia 10 (28.6)
Family history of pancreatic cancer 3 (8.6)
Symptoms 10 (28.6)
Quantitative variables are expressed as mean and standard deviation. Qualitative variables are expressed as absolute values; percentages are indicated in 
parentheses. ASA: American Society of Anesthesiologist classification; AAS: Acetylsalicylic acid.
radiological imaging techniques. Table 3 summarizes the results of cyst fluid analysis. 
CEA levels were not determined in 7/36 (19.4%) PCN due to technical problems 
associated with the high viscosity of the fluid (n = 1; 14.3%) or insufficient sample (n = 
6; 85.7%). In the case of glucose levels, they could not be determined in 6/22 (27.3%) 
because of high viscosity (n = 1; 16.7%) or insufficient sample (n = 5; 83.3%).
Lesion classification
Classification of 2 (5.6%) of the PCN into mucinous or non-mucinous lesions was not 
possible because the mucin stain was negative and no additional CEA or glucose was 
available. The remaining 34 lesions were classified following the algorithm described 
in Figure 1. Twenty-eight (82.4%) were classified as mucinous because they met at 
least one of the criteria and 6 (17.6%) as non-mucinous.
Molecular analysis for the identification of mucinous cystic lesions and malignant 
cysts
The mean volume of liquid sent for molecular analysis was 2.1 ± 2.3 mL. Although cyst 
fluid was initially collected from the 36 PCN, only 25 (69.4%) had the amount of DNA 
needed to perform sequencing (100 ng of DNA at a concentration of 30 ng/µL). The 
cyst fluid volume obtained for molecular analysis in the cases with enough DNA was 
lower (1.8 ± 1.8 mL) compared to those with insufficient DNA (2.7 ± 3.1 mL). No 
statistically significant relationship was found between cyst fluid volume and the 
possibility of performing molecular analysis.
The results of molecular analysis are shown in Table 4. Overall, mutations in KRAS 
were found in 16 (64%) cysts, GNAS in 13 (52%), PIK3R1 in 1 (4%), IDH1 in 1 (4%), 
PDGFRA in 3 (12%), FGFR3 in 2 (8%), RET in 1 (4%), ERBB2 in 1 (4%), BRAF in 1 (4%), 
TGFBR2 in 1 (4%), FBXW7 in 1 (4%) and MAP2K1 in 1 (4%) cyst. No mutations were 
found in the other genes analyzed.
Molecular analysis was possible in 18/28 (64.3%) of the cysts classified as mucinous 
and in 5/6 (83.3%) of the lesions classified as non-mucinous. In addition, sufficient 
DNA was obtained in two lesions that could not be classified as mucinous or non-
mucinous using the cytological and biochemical criteria described in the previous 
section.
Mucinous cystic neoplasms: None of the mutations were associated with mucinous 
cysts (P > 0.05). Mutations in KRAS and GNAS were found in 13/18 (72.2%) and 10/18 
(55.6%) of the cysts classified as mucinous, respectively. KRAS had an 81.2% sensitivity 
(95%CI: 59-100) and 71.4% specificity (95%CI: 30.9-100) (P = 0.297), while GNAS had a 
76.9% sensitivity (95%CI: 50.1-100) and 80% (95%CI: 50.2-100) specificity (P = 0.640) for 
mucinous cyst diagnosis. When combining KRAS and GNAS mutations, 15/18 (83.3%) 
of the mucinous cysts presented mutations in KRAS and/or GNAS, offering an 83.3% 
sensitivity (95%CI: 63.3-100), 60% specificity (95%CI: 7.06-100), 88.24% PPV (95%CI: 
69.98-100) and 50% NPV (95%CI: 1.66-98.34) (P = 0.086) for the detection of mucinous 
cysts.
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Table 2 Morphological characteristics
Radiological imaging tests n (%)
Malignant 7 (19.4)
Non-malignant 29 (80.6)












Size (mm) 27 ± 15.5
Size MPD > 3 mm 11 (30.6)
Mural nodule 8 (22.2)
Contrast enhancement pattern
Hypo/iso-enhanced walls 18 (54.5)
Hyperenhanced walls 12 (36.4)
Mixed enhancement pattern 3 (9.1)
Quantitative variables are expressed as mean ± standard deviation. Quantitative variables are expressed as absolute values, and their proportions are in 
bracketed text. EUS: Endoscopic ultrasound; BD-IPMN: Branch duct intraductal papillary mucinous neoplasm; MD-IPMN: Main duct intraductal papillary 
mucinous neoplasm; MCN: Mucinous cystic neoplasm; SCN: Serous cystic neoplasm; MPD: Main pancreatic duct.
Non-mucinous cystic neoplasms: In a similar manner to mucinous cysts, none of the 
detected mutations were statistically associated with non-mucinous cyst diagnosis. 
Mutations in KRAS and GNAS were found in the same 2/5 (40%) PCN; therefore, the 
combination of both mutations did not provide different results.
Undetermined cystic lesions: Molecular analysis was also performed in 2 (5.6%) PCN 
that could not be classified as mucinous or non-mucinous. One of them had mutations 
in KRAS and GNAS, while no mutations were found in the other cyst.
Malignant cystic neoplasms: Molecular analysis was carried out in 4/5 (80%) of the 
malignant lesions and in 21/31 (67.7%) of the non-malignant lesions. Mutations in 
KRAS and/or GNAS were found in the 4 (100%) lesions classified as malignant and in 
14/21 (66.7%) of the non-malignant lesions. No mutations in PIK3CA were found in 
any of the malignant cysts analyzed. None of the mutations found were related to 
malignancy (P > 0.05).
DISCUSSION
In this study, we evaluated the diagnostic yield of molecular analysis of cyst fluid 
obtained by EUS-FNA for mucinous cyst diagnosis and the detection of malignancy.
Previous studies have shown that mutations present in the histopathological 
analysis of pancreatic tissue obtained from surgical specimens are also present in 
pancreatic cyst fluid, although the amount of DNA obtained from fluid analysis is 
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Table 3 Cyst fluid analysis
Biochemical n (%)
CEA (n = 29)
< 192 ng/mL 14 (48.3)
≥ 192 ng/mL 15 (51.7)
Glucose (n = 16)
< 50 mg/dL 10 (62.5)
≥ 50 mg/dL 6 (37.5)
Cytological









Not possible 11 (30.6)
Quantitative variables are expressed as absolute values, and their proportions are in parentheses. CEA: Carcinoembryonic antigen.
lower and sometimes insufficient for molecular analysis[23,24]. In our series, we obtained 
enough material to perform the molecular analysis (100 ng of DNA at a concentration 
of 30 ng/µL) in 69.4% of included PCN. An insufficient amount of intracystic DNA 
was not associated with a lower volume of fluid obtained. These results are similar to 
those reported in previous studies, which described that the volume required to 
perform molecular analysis ranges between 0.2-0.5 mL, although in some samples the 
amount of DNA is insufficient to perform the analysis[23,25,26]. Therefore, we assume that 
the amount of intracystic DNA is low, and in some cases it may be insufficient to 
perform molecular analysis, providing negative results regardless of cyst fluid volume.
tNGS detected the following mutations: KRAS in 16 (64%) cysts, GNAS in 13 (52%), 
PIK3R1 in 1 (4%), IDH1 in 1 (4%), PDGFRA in 3 (12%), FGFR3 in 2 (8%), RET in 1 (4%), 
ERBB2 in 1 (4%), BRAF in 1 (4%), TGFBR2 in 1 (4%), FBXW7 in 1 (4%) and MAP2K1 in 
1 (4%) cyst. No mutations were found in the rest of the evaluated genes. These results 
are in accordance with those of Jones et al[19], who evaluated 92 pancreatic cysts by 
tNGS for the presence of mutations in 39 genes; they found no mutations in 43% of the 
included cysts and the most frequently detected mutations, as in our series, were 
KRAS and GNAS. In order of decreasing frequency, mutations were found in the 
following genes: KRAS (47%), GNAS (24%), CDKN2A (6%), VHL (2%), SMAD4 (1%) 
and TP53 (1%). We found mutations in KRAS in 72.2% and GNAS in 55.6% of 
mucinous lesions. When combining these results, 83.3% of mucinous cysts harbored a 
mutation in one or both genes. However, neither KRAS nor GNAS or other genes were 
related to mucinous cyst diagnosis (P > 0.05). Regarding the lesions classified as non-
mucinous, mutations were found in KRAS in 40% of these lesions and in GNAS in the 
same 40%. Similar to mucinous cysts, none of the mutations were related to non-
mucinous cyst diagnosis (P > 0.05). We did not find any mutations in VHL. However, 
although its presence has been related to serous cystic neoplasms with high specificity, 
the frequency of this mutation is low. Jones et al[19] analyzed fluid from 92 PCN using 
NSG and found VHL mutations in 2% of them. Springer et al[20] found mutations in 42% 
of histopathologically confirmed serous cystadenomas, although they carried out their 
determination in cyst fluid obtained from surgical specimens and therefore, the 
percentage could be higher.
Some authors have raised the possibility of incorporating molecular analysis of PCN 
due to the high specificity of KRAS and GNAS for mucinous cysts diagnosis found in 
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Table 4 Molecular analysis
Non-mucinous Mucinous
PCN5 PCN15 PCN18 PCN20 PCN33 PCN0 PCN1 PCN2 PCN3 PCN4 PCN7 PCN11 PCN13 PCN14 PCN16 PCN17 PCN19 PCN21 PCN24 PCN25 PCN29 PCN30 PCN34
KRAS M M N N M M N N N N M N N N N M N N N M M N N
GNAS M M N N M N N N N N N N M N N M M N M M M M M
VHL M M M M M M M M M M M M M M M M M M M M M M M
P53 M M M M M M M M M M M M M M M M M M M M M M M
PIK3R1 M M M M M M M M M M M M M M M M M M M N M M M
EGFR M M M M M M M M M M M M M M M M M M M M M M M
ALK M M M M M M M M M M M M M M M M M M M M M M M
NOTCH1 M M M M M M M M M M M M M M M M M M M M M M M
GNA11 M M M M M M M M M M M M M M M M M M M M M M M
CDKN2A M M M M M M M M M M M M M M M M M M M M M M M
APC M M M M M M M M M M M M M M M M M M M M M M M
FGFR2 M M M M M M M M M M M M M M M M M M M M M M M
IDH1 M M M M M M M M M M M M M M M M N M M M M M M
PIK3CA M M M M M M M M M M M M M M M M M M M M M M M
KIT M M M M M M M M M M M M M M M M M M M M M M M
MET M M M M M M M M M M M M M M M M M M M M M M M
FGFR1 M M M M M M M M M M M M M M M M M M M M M M M
ROS1 M M M M M M M M M M M M M M M M M M M M M M M
GNAQ M M M M M M M M M M M M M M M M M M M M M M M
PDGFRA M M M M M M M M N M M M M M M M M M M M N M N
FGFR3 N M M M M M M M M M M M M N M M M M M M M M M
RNF43 M M M M M M M M M M M M M M M M M M M M M M M
RET M M M M M M M M M M M M M M M M M M M M M M N
ERBB2 M M M M M M M M N M M M M M M M M M M M M M M
DDR2 M M M M M M M M M M M M M M M M M M M M M M M
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BRAF M M M M M M M M M M M M M M M M M M M M M N M
ESR1 M M M M M M M M M M M M M M M M M M M M M M M
FGFBR2 M M M M M M N M M M M M M M M M M M M M M M M
FBXW7 M M N M M M M M M M M M M M M M M M M M M M M
FOXL2 M M M M M M M M M M M M M M M M M M M M M M M
MAP2K1 M M M M M M M N M M M M M M M M M M M M M M M
AKT1 M M M M M M M M M M M M M M M M M M M M M M M
CTNNB1 M M M M M M M M M M M M M M M M M M M M M M M
SMAD4 M M M M M M M M M M M M M M M M M M M M M M M
PTEN M M M M M M M M M M M M M M M M M M M M M M M
NRAS M M M M M M M M M M M M M M M M M M M M M M M
IDH2 M M M M M M M M M M M M M M M M M M M M M M M
HRAS M M M M M M M M M M M M M M M M M M M M M M M
CDH1 M M M M M M M M M M M M M M M M M M M M M M M
PCN: Pancreatic cystic neoplasm. M: Mutated; N: Not-mutated.
previous studies with histopathological correlation, and the small volume required for 
their determination[12,19,27,28]. Nikiforova et al[26] performed molecular analysis of cyst 
fluid obtained by EUS-FNA and found that the presence of a KRAS mutation offered a 
sensitivity of 54% and specificity of 100% for mucinous cyst diagnosis[29]. Similarly, 
Amato et al[24] described that KRAS and/or GNAS were mutated in 92% of IPMN, 
GNAS in 79%, KRAS in 50% and both in 37.5%[30]; Singhi et al[23] found mutations in 
GNAS in 39%, KRAS in 68% and both in 83% of IPMN, although only 6% of the MCN 
had mutations in KRAS and/or GNAS[31]. Al-Haddad et al[32] found that the presence of 
a mutation in KRAS and/or ≥ 2 loss of heterozygosity in cyst fluid obtained by EUS-
FNA demonstrated 50% sensitivity and 80% specificity for the diagnosis of mucinous 
cysts. In their study, 58% of the mucinous cysts with histopathological diagnosis did 
not present KRAS mutations. However, molecular analysis allowed adequate 
classification of 24% of the mucinous cysts that could not be classified by CEA and 
cytological analysis. In this study, KRAS offered 81.2% sensitivity and 71.4% 
specificity, GNAS 76.9% sensitivity and 80% specificity, and the combination of KRAS 
with GNAS 83.3% sensitivity and 60% specificity for the diagnosis of mucinous cysts. 
Our sensitivity is close to or higher than that of the studies described above, even in 
those where the fluid was obtained by aspiration of the surgical specimen. On the 
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Figure 1 Diagnostic algorithm for mucinous and non-mucinous cysts. Pseudogold standard was considered positive (mucinous) if: Mucinous histology 
and/or positive mucin staining and/or biochemical > 192 ng/dL and/or glucose < 50 mg/dL, whereas it was considered negative (non-mucinous) if: Non-mucinous 
histology, negative mucin staining, biochemical < 192 ng/dL and glucose > 50 mg/dL. IPMN: Intraductal papillary mucinous neoplasm; MCN: Mucinous cystic 
neoplasm; CEA: Carcinoembryonic antigen.
other hand, our specificity was lower due to the absence of histopathological 
correlation in some lesions, which could have modified the final diagnosis, and the 
smaller population of our series.
Taking into consideration the high specificity of KRAS and GNAS in previous 
studies for the diagnosis of mucinous cysts[26], the 2 (40%) lesions without 
histopathological diagnosis classified as non-mucinous would have been recategorized 
as mucinous after molecular analysis due to the presence of mutations in both KRAS 
and GNAS. This would have led to a modification of the follow-up plan in 8% of the 
cysts in which molecular analysis was successfully performed. Additionally, of the 2 
indeterminate cysts in our study, one showed mutation in both KRAS and GNAS so it 
could have been classified as mucinous. Therefore, we agree that performing 
molecular analysis, at least in selected cases with uncertain diagnosis, could improve 
diagnosis by adequately categorizing PCN as mucinous. This is important as 
mucinous cysts are premalignant lesions and have a higher risk of concomitant 
pancreatic adenocarcinoma, thus implying long-term follow-up. We agree with the 
statement made by other authors about the usefulness of associating the 
determinations of CEA (more sensitive) and KRAS/GNAS (more specific)[24,33]. 
However, further prospective studies with histopathological correlation are needed.
Another area of interest in molecular analysis is the detection of malignancy given 
the low diagnostic accuracy of other diagnostic methods for early detection of 
malignant PCN and the morbimortality associated with pancreatic surgery. In our case 
we were able to evaluate the presence of mutations in 80% of malignant lesions. We 
found mutations in KRAS and/or GNAS in all (100%) malignant lesions, but none of 
these lesions showed mutations in PIK3CA. Additionally, we found mutations in IDH1 
(n = 1) and TGFBR2 (n = 1). In our series no mutations were statistically related to 
malignancy (P > 0.05). Similarly, in previous studies KRAS and GNAS have not been 
related to malignancy and have been described as mutations that occur in the early 
stages of pancreatic carcinogenesis[10,19,25]. In contrast, other mutations such as TP53, 
PIK3CA, PTEN or loss of SMAD4 have been associated with malignancy[10,19,23,34]. Our 
results, similar to those obtained in the study by Singhi et al[23], show that KRAS and 
GNAS are mutations that occur in the early stages of carcinogenesis and are therefore 
present in 100% of malignant mucinous cystic neoplasms. However, they found that 
50% of the IPMNs with high grade dysplasia and 100% of the IPMNs with 
adenocarcinoma had, in addition to the KRAS and/or GNAS mutations, mutations in 
TP53, PIK3CA and/or PTEN. In our study we found no mutations in TP53, PIK3CA or 
PTEN. These differences could be justified by the low incidence of malignancy in our 
sample, differences in the time from extraction to the performance of the molecular 
analysis and differences in the process of molecular analysis.
There are several clinical practice guidelines focused on diagnosis, treatment and 
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follow-up of PCN, with differences in the indication of EUS-FNA, surgery and follow-
up[2,3,11,18,22,35-37]. These differences show the lack of agreement regarding the role and 
indication of this technique, probably due to the challenge of early detection of 
malignancy combined with avoiding unnecessary surgeries. They also reflect 
disagreement in establishing cost-effective follow-up strategies. The AGA guideline 
has been widely criticized for its low diagnostic accuracy for detection of malignant 
cystic lesions, and for its recommendation to discontinue long-term follow-up in the 
absence of significant findings or changes[12,38,39]. In addition, the European guideline 
and the IAP guideline have also been criticized mainly for the high number of 
unnecessary surgeries related to their recommendations[5,40]. Therefore, several authors 
have proposed alternative algorithms based mainly on lowering the threshold for the 
indication of EUS-FNA and on performing molecular analysis[12,41,42].
According to the European guideline[11], we believe it is advisable to continue 
follow-up in mucinous lesions, while it could be discontinued in serous cysts. 
However, differentiation between serous and mucinous PCN is difficult, so the 
European guideline advises performing EUS-FNA with cytological analysis, CEA and 
molecular analysis (NGS) with determination of KRAS and GNAS when the diagnosis 
is unclear[11]. In contrast, the IAP guideline considers that molecular analysis is 
experimental and should only be considered in centers with experience in this 
technique[3]. We have proven that the performance of molecular analysis is a complex 
procedure, with high cost and requires an experienced team; thus, we consider, in line 
with IAP guidelines, that the technique should be standardized before recommending 
its widespread use.
The main strengths of our study are its prospective nature with a cohort of patients 
with different types of PCN (82.4% mucinous and 17.6% non-mucinous cysts) and 
malignancy (13.8%), which shows the standard clinical practice in the study and 
therapeutic decision on PCN, and therefore our experience is applicable to clinical 
practice in any other center with access to pancreatic study techniques. Additionally, 
we performed molecular analysis providing additional information on PCN diagnosis.
However, our study has several limitations. First of all, it is a unicentric study based 
on the experience of a single endoscopist. Second, it should be noted that the diagnosis 
using morphological, cytological and biochemical criteria is suboptimal and we only 
have anatomopathological diagnosis in 5 (13.9%) of the lesions. In fact, as we have 
already discussed, in 2 lesions classified as non-mucinous, initial diagnosis would 
have been modified after performing molecular analysis. We consider that our system 
of classifying the PCN is a good option in clinical practice, where the diagnosis is 
made with the available data in the absence of a surgical specimen. Third, the absence 
of malignancy was defined as the absence of progression in imaging tests or clinical 
deterioration after a follow-up of no less than 6 mo, being the median follow-up in our 
study of 472 (IQR: 271-619) d. However, the follow-up period could be considered 
short and it is uncertain if patients could have developed malignancy over a longer 
follow-up period. Fourth, the small sample size of the study, which was due to the 
short temporal frame of the study and inclusion criteria, resulted in the absence of 
statistical significance. Only lesions ≥ 15 mm were included following the 
recommendations of the European guideline[11], excluding those < 15 mm, even though 
the presence of malignancy was described in up to 39% of the symptomatic cysts < 2 
cm[43]. Finally, we emphasize that, although we consider that molecular analysis is 
highly specific for the diagnosis of mucinous cysts, the high cost of this technique 
precludes its universal implementation.
CONCLUSION
In conclusion, molecular cyst fluid analysis obtained by EUS-FNA helped in our study 
by recategorizing 40% of serous lesions as mucinous cysts. However, the mutations 
detected in our sample did not reach statistical significance for the diagnosis of 
mucinous or malignant cysts. Further studies with larger sample sizes and more 
sensitive techniques could change these results.
ARTICLE HIGHLIGHTS
Research background
Pancreatic cysts are a common finding on imaging tests performed for other reasons. 
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Adequate characterization is important considering the risk of malignancy of some of 
these cysts. However, differentiation between different types of cysts and detection of 
malignancy just with morphological criteria is suboptimal.
Research motivation
Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and molecular 
analysis could improve the detection of mucinous (premalignant) and malignant cysts.
Research objectives
To determine the diagnostic yield of molecular analysis for the detection of mucinous 
and malignant cysts in clinical practice.
Research methods
A single center, prospective observational study of consecutive patients over an 18-mo 
period with pancreatic cystic lesions and an indication for EUS-FNA following 
European clinical practice guidelines was conducted. EUS-FNA with cytological, 
biochemical with CEA and glucose, and molecular analysis with next-generation 
sequencing were performed in 36 pancreatic cysts. Next-generation sequencing results 
were compared for cyst type and malignancy.
Research results
Of the 36 lesions included, 28 (82.4%) were classified as mucinous and 5 (13.9%) 
lesions as malignant. The amount of DNA obtained was sufficient for molecular 
analysis in 25 (69.4%) pancreatic cysts. KRAS and/or GNAS showed 83.33% sensitivity, 
60% specificity, 88.24% PPV and 50% NPV (P = 0.086) for the diagnosis of mucinous 
cystic lesions. Mutations in KRAS and GNAS changed the follow-up plan in 8% of the 
cysts. None of the mutations analyzed were related to malignancy (P > 0.05).
Research conclusions
Molecular cyst fluid analysis obtained by EUS-FNA improved mucinous cyst 
diagnosis by recategorizing 40% of serous lesions as mucinous cysts. However, the 
mutations detected in our cohort did not reach statistical significance to confirm the 
diagnosis of mucinous or malignant cysts.
Research perspectives
Further prospective studies with larger sample sizes are needed to determine the 
clinical benefit of adding molecular cyst fluid analysis for pancreatic cyst evaluation.
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